Zoldonrasib Shows Early Strength in Previously Treated KRAS G12D NSCLC

oncodaily - KRAS G12D has long been one of the most frustrating targets in thoracic oncology. It is biologically important, clearly druggable in theory, and yet patients with KRAS G12D-mutant non-small cell […]

AI Summary: Investigational KRAS(ON) inhibitor zoldonrasib produced effective, durable responses in patients with advanced KRAS G12D–mutated non‑small‑cell lung cancer after prior therapy. Early‑phase data show meaningful tumour shrinkage and a manageable safety profile, offering a targeted option for a mutation long considered untargetable and breathing new life into KRAS drug development.

• Experts on site: RAS inhibitors reshape NSCLC treatment landscape (5)
• Industry moves: BridgeBio reshuffles as KRAS race heats up (1)
• On the AACR floor: zoldonrasib delivers durable G12D responses (4)
• Perioperative and biomarker research reshapes precision care in NSCLC (4)
• All Other Stories

Experts on site: RAS inhibitors reshape NSCLC treatment landscape

Industry moves: BridgeBio reshuffles as KRAS race heats up

On the AACR floor: zoldonrasib delivers durable G12D responses

Perioperative and biomarker research reshapes precision care in NSCLC

All Other Stories